Dermatology · Clinical trials
Chronic Spontaneous Urticaria Clinical Trials
Approved therapies, the pivotal-trial endpoints they were judged on, the magnitude of benefit — and the drugs that failed their endpoints, and why.
Indication overview
About chronic spontaneous urticaria — and why its trials are hard
Chronic spontaneous urticaria (CSU) is defined by recurrent itchy wheals, angioedema, or both, occurring for six weeks or longer without an identifiable external trigger. It is driven largely by mast cell and basophil activation, with both autoimmune (type IIb) and autoallergic (type I) mechanisms, involving IgE, FcepsilonRI signaling, and Bruton tyrosine kinase (BTK). Disease burden is measured with the weekly Urticaria Activity Score (UAS7), the Itch Severity Score (ISS7), and hives counts. Guideline treatment begins with second-generation H1 antihistamines, updosed up to fourfold, but many patients remain symptomatic. Omalizumab, an anti-IgE antibody, was the first biologic approved for antihistamine-refractory disease in 2014. The field has since expanded rapidly: the oral BTK inhibitor remibrutinib and the anti-IL-4/IL-13 antibody dupilumab both gained FDA approval in 2025, offering the first new targeted mechanisms in over a decade for patients who fail antihistamines and biologics.
Approved therapies & pivotal evidence
What's been approved — and by how much it moved the endpoint
| Drug (brand) | Approved | Setting | Pivotal trial | Primary endpoint | Magnitude of benefit |
|---|---|---|---|---|---|
| Omalizumab (Xolair) | 2014 | CSU inadequately controlled by H1 antihistamines, ages 12 and older | ASTERIA I, ASTERIA II, and GLACIAL (Phase 3) | Change from baseline in weekly Itch Severity Score at week 12 | Omalizumab 300 mg reduced ISS7 by roughly 9-10 points versus about 4-5 points on placebo, with a substantial share becoming hive-free |
| Dupilumab (Dupixent) | 2025 | CSU uncontrolled by H1 antihistamines, ages 12 and older (biologic-naive to omalizumab) | LIBERTY-CUPID Study A and Study C (Phase 3) | Change from baseline in ISS7 (and UAS7) at week 24 | Dupilumab produced significantly greater reductions in itch and urticaria activity than placebo; approvals cover H1-antihistamine-refractory disease |
| Remibrutinib (Rhapsido) | 2025 | CSU inadequately controlled by H1 antihistamines; first oral targeted BTK inhibitor | REMIX-1 and REMIX-2 (Phase 3) | Change from baseline in UAS7 at week 12 | Remibrutinib achieved significantly greater UAS7 improvement than placebo, with benefit seen as early as the first weeks and sustained to week 52 |
Where trials have failed
Drugs that missed their endpoint — and what contributed
The most instructive lessons in chronic spontaneous urticaria development come from programmes that failed the endpoint that mattered.
| Drug / trial | Endpoint outcome | What contributed |
|---|---|---|
| Ligelizumab — PEARL 1 and PEARL 2 (Phase 3, Lancet 2023) | Met superiority over placebo but failed the key objective of demonstrating superiority to active comparator omalizumab on UAS7 at week 12 | Higher-affinity anti-IgE binding did not translate into a clinically superior response over omalizumab, undermining the differentiation rationale for the program |
Choosing the right endpoint
Primary endpoints that matter in chronic spontaneous urticaria trials
- UAS7 — Weekly composite of wheal number and itch intensity; the principal disease-activity endpoint in CSU trials
- ISS7 — Weekly itch severity score; often the primary endpoint for regulatory filings including omalizumab and dupilumab
- UAS7 = 0 — Complete response (no hives, no itch); a stringent secondary endpoint reflecting full remission
- DLQI — Dermatology Life Quality Index capturing patient-reported impact on daily life
How iNGENū runs chronic spontaneous urticaria trials
Physician-led design, built for FDA submission
Endpoint & biomarker strategy
Board-certified specialists design endpoints and patient selection aligned to current FDA guidance for this indication.
FDA-ready data
Built to ICH-GCP and 21 CFR 312.120, with direct FDA submission — data accepted by the FDA, EMA and MHRA.
Faster, lower-cost delivery
~4-week ethics via the TGA CTN scheme, up to 43.5% R&D rebate, and 80–90% below US CRO cost.
Request a fixed-milestone proposal and a tailored endpoint & feasibility summary for this indication.
Frequently asked questions
Chronic Spontaneous Urticaria clinical trials — FAQs
What is first-line treatment for CSU?
What options exist if antihistamines and omalizumab fail?
How is treatment response measured?
Ready to discuss your chronic spontaneous urticaria trial?
Talk to our physician-led team about an FDA-ready, cost-efficient trial design.
Request a proposal